10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA
Earnings Release
News
Announces Pricing of Upsized $90.0 Million Public Offering
Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis (RRMS)
Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Investor Presentation
Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report